samedan logo
 
 
spacer
home > pmps > spring 2003 > changing to washing-in-place - a major step towards the future?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Changing to Washing-in-Place - A Major Step Towards the Future?

Washing-in-place (WiP) technology has been developed to keep up with changes in the pharmaceutical industry in order to reduce downtimes. The washing-in-place concept can be enhanced through faster product change and reduced workplace contamination with the new WiP generation of tablet presses. However, the benefits and secondary advantages of this technology are as yet unclear and this article will attempt to reveal them.

The Economic Approach to WiP Tablet Presses

Economic constraints are the same all over the world. The need for precise, total production planning in all areas of the pharmaceutical industry forms the basis for minimised stocks and timely production. This in turn requires calculable, definitive production times and short, feasible cleaning times.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ines Andersen, Pharmaceuticals Product Manager at Wilhelm Fette GmbH

Ines Andersen is Pharmaceuticals Product Manager and an Economic Engineer at Wilhelm Fette GmbH. Ms Andersen has worked in the chemicals and pharmaceuticals industry in Germany and the United States for over 10 years, six of which she has spent in product management and marketing. She has a degree in Economic Engineering.

Ms Andersen joined Wilhelm Fette in January 2001. As Product Manager she is responsible for the entire product portfolio and is in charge of all the company's marketing activities worldwide.

spacer
Ines Andersen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement